Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Send us Your BIO 2016 Session and Speaker Ideas

BIO International Convention

Even though BIO 2015 in Philadelphia was just two months ago, we already are hard at work getting ready for 2016 and the BIO International Convention in San Francisco (June 6-9, 2016). Our team at BIO is always imagining new ways to improve your experience, to make the most of your time and your meetings and to ensure that you are hearing directly from the key science, policy and investment leaders that allow you to Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

When The Deck is Stacked Against Innovators, Everyone Loses

US_Patent_And_Trademark_Office

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the USPTO’s Inter Partes Review system (IPR). Joined by several of BIO’s member companies, we expressed our concerns with how the system is evolving into one which makes it easier for IPR challengers to win than in Federal Court. The implementation of the IPR system – developed through the 2011 America Invests Act – has unintentionally invited abuses of the USPTO Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Unleashing the Full Promise of Biotechnology Innovation

Jim Greenwood

Last week, I attended the announcement of President Obama’s Precision Medicine Initiative at the White House. In the room were leading biotechnology executives, researchers, lawmakers from both parties, regulatory officials and patients. Seated just a few rows in front of me was a young man named Bill Elder whose life has been transformed by a cystic fibrosis drug developed by one of our member companies, Vertex. Today, Bill is a third-year medical student with an Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Jim Greenwood

Biosimilars raise novel and complex questions of science and law that require updated legal and regulatory frameworks. We call on the FDA to release final guidance on processes and scientific criteria for the approval of biosimilars, outline its approach to naming and labeling, and clarify its conditions for determining a biosimilar to be interchangeable with its reference biological. There has been positive momentum recently, however, we believe the appropriate way to develop policy on such Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Attacks on Venture Philanthropy Miss Mark Badly

Jim Greenwood

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy and patient foundation funding of medical research, which has become a valuable source of funding for diseases which may not otherwise receive research dollars. Venture philanthropy organizations bring a singular focus and drive to the process of getting promising therapies from the laboratory bench to the patient as quickly and efficiently as possible, bringing hope – and results – to Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,